ISRCTN23348591已完成未知
A placebo controlled study of the effect of EXTended treatment with Rituximab on resistant Rheumatoid Arthritis: Clinical and radiological outcomes
niversity of Leeds (UK)0 个研究点目标入组 60 人开始时间: 2008年3月27日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 60
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Able and willing to give written informed consent and comply with the requirements of the study protocol
- •2. Patients with rheumatoid arthritis for at least 6 months, diagnosed according to the revised 1987 American College of Rheumatology (ACR) criteria for the classification of rheumatoid arthritis
- •3. Patients who have experienced an inadequate response to previous or current treatment with etanercept, infliximab or adalimumab because of toxicity or inadequate efficiency (etanercept for >3 months at 25 mg twice weekly, at least 4 infusions of infliximab at >=3 mg/kg or adalimumab for >=3 months at 40 mg every other week) or be unsuitable for treatment with anti-TNF therapy because of contra-indication
- •4. Patients who have been washed out from etanercept, infliximab or adalimumab or ¡Ý4 weeks prior to treatment with rituximab
- •5. All Disease Modifying Anti-Rheumatic Drugs (DMARDs) other than methotrexate should be withdrawn at least 4 weeks prior to rituximab therapy (see above for anti-TNF therapy)
- •6. 28-item Disease Activity Score (DAS28) >3.2
- •7. Age 18-80 years
- •8. Corticosteroids (<=10 mg/day prednisolone or equivalent) permitted if stable for at least 4 weeks prior to screening and NSAIDs permitted if stable for at least 2 weeks prior to screening.
- •9. Patients of reproductive potential (males and females) using a reliable means of contraception (e.g., contraceptive pill, IntraUterine Device [IUD], physical barrier)
- •10. If female and of childbearing potential, a negative urine pregnancy test within two weeks prior to therapy
- •11. Presence of erosive joint disease of at least 1 joint on x-ray (except if Distal InterPhalangeal [DIP] joint of the hand)
排除标准
- •1. Bone/joint surgery within 8 weeks prior to therapy or joint surgery planned within 24 weeks of therapy
- •2. Rheumatic autoimmune disease other than RA or significant systemic involvement secondary to RA
- •3. History of, or current, inflammatory joint disease other than RA or other systemic rheumatic disorder
- •Excluded previous/concomitant medications:
- •1. Concurrent treatment with any DMARD (apart from methotrexate) or any anti-TNF therapy or other biologic agent
- •2. Treatment with any investigational agent within 4 weeks of screening or 5 half lives of the investigational drug
- •3. Previous treatment with any cell depleting therapy therapies including investigational agents (e.g., CAMPATH®, anti-CD4, anti-CD5, anti-CD3, antiCD19)
- •4. Intra-articular or parenteral steroids within 4 weeks prior to therapy except for joints undergoing arthroscopy and/or Magnetic Resonance Imaging (MRI) where IA steroids are not permitted within 12 weeks prior to therapy
- •5. Receipt of a live vaccine within 4 weeks prior to randomisation
- •Exclusions for General Safety:
- •1. History of severe allergic or anaphylactic reactions to humanised or murine monoclonal antibodies (e.g., infliximab or adalimumab)
- •2. Evidence of significant uncontrolled concomitant diseases such as cardiovascular disease, nervous system, pulmonary, renal, hepatic, endocrine or gastrointestinal disorders
- •3. Known active bacterial, viral, fungal mycobacterial infection (including tuberculosis, or atypical mycobacterial disease but excluding fungal infection of the nailbeds) or any episode of infection requiring hospitalisation or treatment with intravenous (iv) antibiotics within 4 weeks of therapy or oral antibiotics within 2 weeks of therapy
- •4. History of, or currently active, primary or secondary immunodeficiency
- •5. History of solid organ malignancy in the past 5 years (excluding basal cell or squamous cell carcinomas of the skin which have been excised and cured)
- •6. Pregnant women or breastfeeding mothers
- •7. History of alcohol, drug or chemical abuse within 6 months prior to screening
- •8. Neuropathies or neurovasculopathies which might interfere with pain evaluation
- •9. Intolerance or contraindications to oral (po) or iv steroids
- •Laboratory exclusion criteria (at screening):
- •1. Serum creatinine >140 mmol/l
- •2. ASpartate aminoTransferase (AST) or ALanine aminoTransferase (ALT) >2.5 times upper limit of normal
- •3. Platelet count <100
- •4. Haemoglobin <8.5
- •5. Neutrophils <1.5x10.3/µl
- •6. Positive tests for hepatitis B surface antigen or hepatitis C antibody
- •7. Levels of IgG and/or IgM below 5.65 and 0.55 mg/mL respectively
研究者
相似试验
进行中（未招募）
不适用
effect of Lactobacillus GG on tolerance acquisition in children with cow's milk allergyChildren with cow's milk allergyOral and Gastrointestinal - Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colonDiet and Nutrition - Other diet and nutrition disordersACTRN12610000566033Dipartment of Pediatrics University of Naples Federico II66
尚未招募
3 期
A clinical trial to study the add on effect of two drugs, Pippalyadi Churna with Lodhradi Yonivarti in the management of kaphaj Yonivyapad with special reference to Vaginitis.CTRI/2024/06/069357Ashwini Ramchandra Metangale
已完成
不适用
Study on the effect of alpha glucosidase inhibitors on glycemic variability in patients of type 1 diabetes mellitusCTRI/2023/01/049038Institutional39
尚未招募
Unknown
A study using augmented reality to decrease anxiety in children before anesthesia.CTRI/2024/05/067987Maulana Azad medical College
进行中（未招募）
1 期
A PLACEBO CONTROLLED STUDY OF THE EFFECT OF EXTENDED TREATMENT WITH RITUXIMAB ON RESISTANT RHEUMATOID ARTHRITIS: - EXXTRARheumatoid arthritisEUCTR2006-005640-81-GBniversity of Leeds60